Background: In 2006, the world's first quadrivalent human papillomavirus (HPV) vaccine (Gardasil) was made available to the Australian public. The quadrivalent HPV vaccine protects against cervical cancer, cervical abnormalities, and genital warts related to HPV types 6, 11, 16 and 18. General practitioners play a vital role in preventive medicine and as such should have a good understanding of the vaccine and its role in the primary prevention of cervical cancer and precancers.
Objective: This article provides an overview of the HPV vaccine including efficacy and safety as it relates to its approved use in Australia.
Discussion: The vaccine (Gardasil) is quadrivalent, providing protection against HPV types 6, 11, 16 and 18. These HPV types represent a significant burden on public health as they are responsible for 70% of cervical cancers, a substantial proportion of cervical abnormalities, and 90% of genital warts. The quadrivalent HPV vaccine (Gardasil) is indicated for females aged 9-26 years and males aged 9-15 years and should ideally be administered before the onset of sexual activity, however sexually active patients will also benefit.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Meeting summary: Global vaccine and immunization research forum, 2023.
Vaccine
January 2025
Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, MSC 9825, Bethesda, MD 20892-9825, USA. Electronic address:
At the 2023 Global Vaccine and Immunization Research Forum (GVIRF), researchers from around the world gathered in the Republic of Korea to discuss advances and opportunities in vaccines and immunization. Many stakeholders are applying the lessons of Covid-19 to future emergencies, by advancing early-stage development of prototype vaccines to accelerate response to the next emerging infectious disease, and by building regional vaccine research, development, and manufacturing capacity to speed equitable access to vaccines in the next emergency. Recent vaccine licensures include: respiratory syncytial virus vaccines, both for the elderly and to protect infants through maternal immunization; a new dengue virus vaccine; and licensure of Covid-19 vaccines previously marketed under emergency use authorizations.
View Article and Find Full Text PDFRecruitment of Young Gay, Bisexual, and Other Men Who Have Sex With Men for a Web-Based Human Papillomavirus Vaccination Intervention: Differences in Participant Characteristics and Study Engagement by Recruitment Source in a Randomized Controlled Trial.
J Med Internet Res
January 2025
College of Public Health, The Ohio State University, Columbus, OH, United States.
Background: Young gay, bisexual, and other men who have sex with men have been referred to as a "hard-to-reach" or "hidden" community in terms of recruiting for research studies. With widespread internet use among this group and young adults in general, web-based avenues represent an important approach for reaching and recruiting members of this community. However, little is known about how participants recruited from various web-based sources may differ from one another.
View Article and Find Full Text PDFPrevention of gynecological cancers: cervical cancer screening in Turkey: a role model for the world.
Curr Opin Obstet Gynecol
February 2025
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Faculty of Medicine, Hacettepe University.
Purpose Of Review: This review examines Turkey's cervical cancer screening programme, highlighting its evolution from a cytology-based approach to a more effective HPV-based strategy. The review is timely given the global push to reduce cervical cancer incidence through improved screening practices, and it positions Turkey's programme as a potential model for other countries facing similar public health challenges.
Recent Findings: Recent advances in cervical cancer screening in Turkey include the nationwide introduction of HPV DNA testing, centralized laboratory systems and innovative management software.
HPV genotypes in invasive cervical cancer: prevalence, risk attribution, and optimized vaccine strategies in western China.
Front Public Health
January 2025
Department of Pathology, West China Second University Hospital, Sichuan University, Chengdu, China.
Background: Understanding the HPV genotype distribution in invasive cervical cancer (ICC) is essential for vaccine optimization. This study presents a comprehensive analysis of HPV genotypes in ICC tissues from patients in western China, with the aim of informing regional vaccine policy and prevention strategies.
Methods: DNA was extracted from 1,908 paraffin-embedded ICC samples, and 23 HPV genotypes were detected via PCR and reverse dot hybridization gene chip assays.
Impacts of the US CDC recommendation on human papillomavirus vaccine uptake, 2010-2015.
Front Public Health
January 2025
Department of Health Administration and Policy, University of Oklahoma Health Sciences Center, Oklahoma, OK, United States.
Objectives: As one type of vaccine policy, the effectiveness and spillover effects of the US CDC vaccine recommendations are inadequately evaluated. This study aims to fully evaluate its impacts on male adults, in addition to children, using better data.
Design: A before-after study design to examine the CDC's 2011 HPV vaccine recommendation for men aged 11-21.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!